Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 4, 2012
Last updated: August 31, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)